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    Since the recombinant plasmid was first introduced into E.coli 
by Cohen et al. [1] in 1973, genetic engineering (modification) 
has been developing rapidly. Genetic modifications in vivo or in 
vitro, which have an effect on the expression of specific proteins, 
such as channel, receptor, enzyme, and signals, are actively 
applied in the researches that highlight the relationship between 
the effects of anesthetics and functions of specific proteins [2-
5]. The loss-of-function studies that control the function of 
proteins, are very important in clarifying the mechanism of 
action of anesthetics. To achieve this, post-translational proteins 
are directly inhibited by pharmacological inhibitors [6,7], or 
are indirectly suppressed by transforming DNA construct via 
mutation or recombination, which is known as transgenic 
knockout technique [8]. After the creation of knockout mice 
by Capecchi et al. in 1989, transgenic knockout techniques 
are not only available in vitro, but are also available in vivo 
animal studies (In 2007, Capecchi MR won a nobel prize in 
appreciation for creating transgenic knockout mice). Although 
the gene knockout technique has several advantages over 
conventional laboratory techniques, including a long-lasting 
and a definitive specific gene-silencing effect, it is not easy to 
get a genetic engineering technique and initially it is expensive 
to purchase a gene knockout animal. After the discovery of RNA 
interference (RNAi) that is induced by short sequence-specific 
double stranded RNA (dsRNA) ranging in size from 20 to 25 
nucleotides in length, and that targets the complementary sites 
on mRNA, exogenous synthetic small interfering RNA (siRNA) 
could be used to induce post-transcriptional gene silencing and 
that was first applied in mammalian cells in 2001 [9]. Because 
well-designed siRNA can induce suppression of any gene 
through forming the RNA- induced silencing complex (RISC) in 
the cytoplasm, the research for therapeutic application of siRNA 
against cancer, viral infection, and neurodegenerative disease 
are now being performed and clinical trials are also being 
carried out [10,11]. Moreover, if methods for effective in vivo 
delivery of siRNAs into the target tissue or organ are developed, 
anesthesiologists could easily achieve control over the tissue or 
organ-specific expression of individual target proteins used in 
the research. It is known that systemically or locally delivered 
siRNA induces a temporary gene expression knockdown effect 
by up to 90% from 48 hours to 3 weeks in animal experiments 
for eyes, brain, spinal cord, lungs, subcutaneous tissue, vagina, 
skin, isolated tumor, heart et al. [10-12]. But systemically or 
locally administered siRNA is easily degraded during the 
phase of delivery to the target cells by endogenous enzymes 
or phagocytosis, and its permeation through the negatively 
charged hydrophobic cellular membranes is difficult because 
of its high molecular weight (~13 kDa) and its too negatively 
charged character. Also, the cytoplasmic concentration of 
transfected siRNA is reduced as cell divisions progress and, 
cell types and pericellular factors influencing cell division may 
influence the gene silencing effects over time [13]. In general, 
the small size of the siRNA is considered not to provoke cytosolic 
dsRNA-mediated interferon response. But, it is reported that 
transfected siRNA is linked to the production of interferon and 
interleukin in some cell types (plasmacytoid dentritic cells, 
macrophages), that may be related to immunotoxicity. And, it 
is also known that a siRNA could degrade not only the targeted 370 www.ekja.org
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mRNAs but also the unintended mRNAs with sequence 
homology with the siRNA, which is called the “off-target 
effect” . As a result, there is a chance of inaccurate results in the 
experiments undertaken using the suppression of a specific 
protein and even for assessing the cytotoxicity. To correct such 
shortcomings, it is recommended that the administered doses 
of siRNA should be reduced while constructing the design of 
experiments for successful delivery of siRNA into a target cell 
or tissue. And, the nucleotide modifications of siRNA can be 
applied in order to prevent the ‘off-target effect’ [13]. Ki et al. [14] 
in this month’s journal found the lowest concentration of siRNA 
against a specific protein that could not only induce effective 
transfection of siRNA but also show maximum RNAi-mediated 
gene silencing while not demonstrating cytotoxicity, both in 
the cultured astrocytes and microglial cells [14]. Identifying 
the lowest effective concentration of siRNA is desirable for 
minimizing the adverse reactions and also for improving the 
cost-effectiveness for researchers who are always confronted 
with the problem of lack of financial support for experiments. 
Although Ki et al. [14] have clarified that each cell type has its 
own characteristic for determining the lowest concentration of 
siRNA against a specific protein at which the targeted mRNA is 
effectively silenced (5 nM for astrocytes, 20 nM for microglial 
cells), it was not determined whether that concentration of 
siRNA in each cell is related to the ‘off-target effect’ (knockdown 
of untargeted proteins). Tschuch et al. [15] reported that 5 nM 
siRNA against green fluorescent protein (GFP), which was 
the protein used in the study by Ki et al. [14], can suppress 
the expression of the other unintended proteins (CYLD and 
SOAT) in HeLa and HEK cells. This fact implies that untargeted 
proteins may also be suppressed by 20 nM siRNA against GFP, 
the lowest concentration suppressing the target gene expression 
both in the astrocytes and microglial cells in the study by Ki 
et al. [14], and thereby the accuracy of results of the study 
may be adversely affected. Thus before performing research 
using the procedure for siRNA silencing of expression of a 
specific protein, it is necessary not only to find out the lowest 
concentration at which a target protein could be controlled, 
but also to investigate the concentration of siRNA at which 
cellular apoptosis and expression of stress-response proteins 
are not triggered [16]. Ki et al. [14] tried to estimate the degree of 
cytotoxicity at the measured concentration of siRNA using the 
MTT assay, by which cell viability can be assessed. At present, 
control of protein expression by siRNA-induced transcriptional 
gene silencing is on the rise in the field of laboratory research. 
But, siRNA can provoke ‘off-target effect’ and immuno-
modulation, and the time course of siRNA-induced gene 
silencing is still unclear. So, results of the study may be adversely 
affected. Further research is needed to confirm the accuracy of 
results of the RNA interference experiments using siRNA. 
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